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Research Article 
Novelty and Impact: Environmental chemicals with hormonal properties, also called 
endocrine-disrupting chemicals are suspected to favor the occurrence of prostate cancer. 
These chemicals are obviously still present at the beginning of therapy, and beyond, and 
consequently they could influence the treatment outcome. Here we report for the first time 
that exposure to the estrogenic insecticide chlordecone, determined at the time of diagnosis, 
increases the risk of biochemical recurrence after radical prostatectomy of organ-confined 
disease.  
Abstract 
Previous studies have suggested that exposure to environmental chemicals with hormonal 
properties, also called endocrine disrupting chemicals, may be involved in the occurrence of 
prostate cancer. Such exposure may also influence the treatment outcome as it is still present 
at the time of diagnosis, the beginning of therapy, and beyond. We followed 326 men in 
Guadeloupe (French West Indies) who underwent radical prostatectomy as primary treatment 
of localized prostate cancer.  We analyzed the relationship between exposure to the 
estrogenic chlordecone, the anti-androgenic dichlorodiphenyldichloroethylene (DDE, the 
main metabolite of the insecticide DDT), and the non-dioxin-like polychlorinated biphenyl 
congener 153 (PCB-153) with mixed estrogenic/anti-estrogenic properties and the risk of 
biochemical recurrence after surgery. After a median follow-up of 6.1 years after surgery, we 
found a significant increase in the risk of biochemical recurrence, with increasing plasma 
chlordecone concentration (adjusted hazard ratio = 2.51; 95% Confidence Interval: 1.39-4.56 
for the highest versus lowest quartile of exposure; p trend = 0.002). We found no associations 
for DDE or PCB-135.  These results shown that exposure to environmental estrogens may 
negatively influence the outcome of prostate cancer treatment. 
Introduction 
Prostate cancer is the most common hormone-sensitive malignancy in men.1 Endogenous 
steroid sex hormones play a key role in the initiation and progression of this disease.2  
In vitro and in vivo experimental research has increasingly suggested that 
environmental chemicals with hormonal properties, also called endocrine-disrupting 
chemicals (EDCs), particularly those that mimic steroid sex hormones, may modulate the risk 
of developing prostate cancer.3-5. Among these, persistent organic pollutants (POPs) have 
attracted attention because of their long-term presence in the environment and for some of 
them their ability to interfere with steroid sex hormone-regulated processes. 6-10 
Several epidemiological studies using exposure biomarkers have been conducted to 
investigate the relationship between human exposure to POPs with hormonal properties 
during adulthood and the risk of prostate cancer.11-19 Conclusions have been divergent, 
sometimes even demonstrating associations in opposite directions, depending on the chemical 
considered or the aggressiveness of the disease at the time of diagnosis. Such disparities may 
be explained by the different hormonal properties of these compounds, agonistic or 
antagonistic, on different members of the steroid sex receptor superfamily, the clinical and 
molecular heterogeneity of the disease, or differences in exposure windows.  
The influence of human exposure to EDCs on the development of prostate cancer is 
still an open question. Nonetheless, patients are still exposed at the time of diagnosis and 
subsequent treatment. This raises the question of the influence of EDCs on disease 
progression after treatment.  Surgical resection of the entire gland, radical prostatectomy, is a 
common therapeutic option, for curative purposes, for men with organ confined prostate 
cancer.  However, approximately 20-40% of patients will present biochemical recurrence 
(rising prostate-specific antigen, PSA) of the disease.  Many studies, have identified clinical 
and pathological features to be significant risk factors of biochemical recurrence 20-22 but 
nothing is known about the influence of environmental chemicals 
We sought to analyze the association between blood concentrations of various POPs at 
the time of diagnosis and the risk of biochemical recurrence after radical prostatectomy, a 
common surgical procedure for the complete removal of the prostate for men with clinically 
organ-confined prostate cancer.  
Among POPs, we have focused our attention on the most prevalent ones such as the 
estrogenic insecticide chlordecone, the anti-androgenic p, p’-
dichlorodiphenyldichloroethylene (DDE, the main and most stable metabolite of the 
insecticide p, p’-dichlorodiphenyltrichloroethane, DDT), and the non-dioxin-like 
polychlorinated biphenyl congener 153 (PCB-153), which displays both estrogenic and anti-
estrogenic properties.   
Material and Methods 
Study population  
This study took place in Guadeloupe (French West Indies), a Caribbean archipelago, where 
most of the inhabitants are of African descent. It was prospectively conducted on incident 
prostate cancer patients who initially participated in a population-based case-control study 
between June 2004 and December 2007,14 subsequently underwent radical prostatectomy in 
one single center (Urology Department of the University Hospital of Guadeloupe) (n = 392), 
and from whom we were able to obtain plasma samples and determine the POPs 
concentrations one to three months before surgery (n = 340). All patients were followed by 
serial PSA determinations and clinical visits every six months for the first three years after 
surgery and annually thereafter. Biochemical recurrence was defined as two consecutive 
(usually four weeks apart) PSA measurements above 0.2 ng/ml, with the date of the first 
increase after nadir as the recurrence date.23 Fourteen patients were excluded because they 
were treated with neoadjuvant hormonal therapy or radiotherapy or because the PSA value did 
not return below 0.2 ng/ml six weeks after surgery. The study was approved by the 
Guadeloupean ethics committee for studies involving human subjects. Each participant 
received, completed, and signed written informed consent. 
Before surgery, we collected information on the demographic characteristics, 
Caribbean origin (French West Indies, Haiti or Dominica), education (primary, secondary, 
high school or higher), weight and height allowing the calculation of body mass index 
(kilograms per meter squared), smoking (never, former or current), alcohol consumption 
(never, former, or current), diabetes type 2 (no, yes), and family history of prostate cancer 
(first degree relatives: no, yes, not known), and preoperative PSA level. After surgery, we 
collected data on the pathological stage, prostatectomy ISUP Gleason grade,24  surgical 
margins, tumour density, and follow-up PSA levels.  
Laboratory Assays.  
A high-resolution gas chromatograph (Thermo Quest Trace 2000, Milan, Italy) equipped with 
a Ni63 electron capture detection system was used to determine the blood concentration of 
chlordecone, p,p´-DDT, p,p´-DDD (dichlorodiphenyldichloroethane), p,p´-DDE, the α, β, and 
γ isomers of hexa-chlorocyclohexane (HCH), and 24 PCB congeners (International Union of 
Pure and Applied Chemistry number): 6 dioxin-like (77, 105, 118, 126, 156, and 169) and 18 
non-dioxin-like (18, 28, 52, 101, 110, 128, 138, 143, 149, 153, 170, 180, 183, 187, 194, 195, 
206, and 209).  The limit of detection (LOD) was 0.05 µg/L for all POPs except 0.06 µg/L for 
chlordécone (0.06 µg/L).12. Detailed information about sampling, analysis, and quality 
assurance and control has been provided elsewhere. 14, 25  Plasma total cholesterol and total 
triglyceride concentrations were determined enzymatically (DiaSys Diagnostic Systems 
GmbH; Holzheim, Germany) and total lipid concentration was calculated as previously 
described. 26 
Statistical Analysis.  
We restricted our analysis to chemicals detected at a rate of more than 80% (DDE; PCB 
congeners 138, 153, and 180; and chlordecone). Correlations between concentrations of the 
frequently detected PCBs were explored by Spearman’s rank correlation analysis (Supporting 
information, supplemental Table 1). The concentrations of the various PCBs were highly 
correlated (Spearman’s rho ≥ 0.75; all p-values < 0.001), so we restricted further analysis to 
PCB-153. 
Plasma POPs concentrations were categorized into quartiles, based on their 
distribution among patients. Time to event was defined as the duration between the date of 
surgery and the PSA value that defined the recurrence event. Patients who did not relapse, or 
were lost to follow-up, were censored at the last normal post-operative PSA measurement 
before October 30, 2017. Five-year BCR-free survival analysis were carried out using the 
Kaplan−Meier method and log-rank test for trend. The Cox proportional hazards method was 
used to compute adjusted survival curves and test for trend were assessed with quartiles of 
exposure scored as ordinal variables in ascending order. We also used multivariable Cox 
proportional hazards regression models and 95% confidence intervals (CI) to estimate the 
hazard ratio (HR) of biochemical recurrence associated with POPs exposure. Potential 
confounders were included in all statistical models if they predicted (p < 0.05) biochemical 
recurrence status: body mass index, family history of prostate cancer, pathological Gleason 
grade, pathological stage, surgical margins, tumor density (Table 1) and then selected by 
applying a backward selection procedure at p < 0.1. Missing data for covariates varied from 
none to two (0.6 %) for education, two (0.6 %) for alcohol, two (0.6 %) for family history of 
prostate cancer, three (0.9 %) for smoking, and eight (2.5 %) for diabetes. Missing data were 
handled using missing value indicator categories. The proportional hazards assumption was 
verified by the log-negative-log survival distribution function of all variables. Tests for linear 
trend across exposure categories were performed, with the natural log transformed POPs 
concentration treated as a continuous variable. Exposure levels equal to or below the LOD 
were estimated by a maximum likelihood estimation method.27 Sensitivity analyses were 
conducted by excluding patients with positive surgical margins or prostatectomy ISUP 
Gleason grade 3 or higher, or advanced pathological stage (pT3 or pT4 or N+). Statistical 
analyses were carried out using SAS software version 9.3 (SAS Institute, Cary, NC, USA). 
All tests were two-sided, and p < 0.05 were considered statistically significant. 
Results 
The results presented here were obtained from a study population of 326 patients. During 
1,923 person-years of follow-up after surgery, 93 men (28.5%) experienced biochemical 
recurrence. The median follow-up time was 6.1 years and among men without progression 7.3 
years. The baseline characteristics of the study population and HR for risk of biochemical 
recurrence are presented in Table 1. Detection levels and plasma concentrations of POPs are 
presented in Table 2.   
The crude five-year BCR-free survival rates were 83.8%, 79.8%, 86.6%, and 65% for men in 
the 1st, 2rd, 3rd, and 4th quartile of chlordecone exposure, respectively (Log-rank test for trend, 
p = 0.01). For DDE and PCB-153 exposure, the five-year biochemical recurrence-free 
survival rates were 78.7, 83.8, 70.7, and 81.1 and 81.5, 79.0, 79.7, and 75.0 for men in the 1st 
to 4th quartile, respectively (DDE: Log-rank test for trend, p  = 0.85; PCB-153:  Log-rank test 
for trend, p = 0.83). Crude and adjusted survival curves are presented in supporting 
information (supplemental figures 1 to 3).  
Adjusted Cox analysis showed that men in the highest quartile of chlordecone plasma 
concentration had a significantly higher risk of biochemical recurrence than those in the 
lowest quartile (HR= 2.51, 95% CI: 1.39-4.56) (Table 3). The linear relationship between 
exposure and response was significant (p-trend = 0.002). We obtained comparable results if 
DDE and PCB-153 concentrations were additionally included in the multivariable model 
(HR= 2.62, 95% CI: 1.40-4.90 for the highest quartile relative to the lowest quartile; p-trend = 
0.002). DDE and PCB-153 exposure were not associated with a risk of BCR, irrespective of 
the model (Table 3). 
Sensitivity analysis revealed that chlordecone exposure was still significantly 
associated with a risk of BCR after excluding patients with positive surgical margins or 
prostatectomy ISUP Gleason grade 3 or higher, or advanced pathological stage (Table 4). 
Men who were in the highest quartile of chlordecone plasma concentration had a higher risk 
of BCR than those in the lowest quartile (Adjusted HR = 2.98, 95% CI: 1.06-8.38) and the 
linear relationship between exposure and response was significant (p-trend = 0.003). Here 
again, DDE and PCB-153 exposure were not associated with a risk of BCR (Table 4).   
Discussion 
This is the first study to investigate the association of POPs plasma concentrations, measured 
at the time of diagnosis, with biochemical recurrence following primary curative surgical 
treatment of prostate cancer. 
In our study population, the highest quartile of exposure to chlordecone was 
consistently associated with a more than two-fold increased risk of biochemical recurrence, 
with a significant exposure-response relationship. This was still true after taking into account 
well-known prognostic clinic-pathological features of biochemical recurrence as confounding 
factors and in sensitivity analysis restricted to patients who did not present these adverse 
clinic-pathological features. In contrast, exposure to DDE or PCB-153 was not associated 
with BCR.  
Chlordecone was extensively used from 1973 to 1993 in the French West Indies, to 
control the banana root borer. This pesticide undergoes no significant biotic or abiotic 
degradation in the environment, so permanently polluted soils and waters have remained the 
primary source of foodstuffs contamination, and human beings  continue to be exposed to this 
chemical 28.  In our study population, chlordecone plasma concentration was in the range of 
values observed for residents in the neighborhoods near the chlordecone factory in Hopewell 
(VA, U.S.). 29 Such exposure resulted from the air pollution and illegal dumping of waste 
laden into Hopewell's sewer system which in turn contaminated the James River and fish 
resources.  There is currently no data on exposure to chlordecone in other populations. 
Concerning other POPs,  DDE and PCB congeners 138, 153, and 180 were the most prevalent 
found in the blood in our population, as expected and found in most populations worldwide. 
Moreover, blood concentrations of these pollutants are in the range of background 
environmental levels currently found in the US population of similar age range 30. This is not 
surprising, because the use of DDT in agricultural supplies or for disease vector control in the 
French West Indies was sporadic and industrial activities involving the significant use or 
emission of PCBs has only been very limited. Consequently, exposure to these chemicals is 
likely to be associated with background contamination of the food chain. 
Biomonitoring of human tissues is considered to be a gold standard approach for 
assessing aggregated environmental chemical exposure, because it integrates all sources of 
exposure from different absorption pathways.31 The exposure to POPs observed in this study 
was assessed based on plasma concentrations at the time of diagnosis, prior to surgery, and 
before the outcome occurrence. These chemicals have a long half-life in the body, varying 
from six months for chlordecone to several years for DDE and PCB-153. Although the use of 
POPs is mostly banned worldwide, they are still present in the environment and populations 
are continuously exposed through food consumption. Thus, a single measurement of POPs 
concentration in the blood reflects the body burden under steady-state conditions and provides 
a sufficiently confident estimation of exposure over an extended period. However, the levels 
of each POPs varies depending on the type of foodstuffs (i.e. chlordecone is preferentially 
found in root vegetables, fish, and meat of local origin, DDE in food crops, fish and meat, and 
PCB in meat and milk). Thus, any significant changes in dietary habits may result in changes 
in the body burden over several years. However, no specific dietary recommendations have 
been made and we are not aware of any changes in the dietary habits of our patients after 
surgery.  
Although radical prostatectomy is considered as a definitive therapy for organ-
confined prostate cancer, an increase in PSA levels after a variable period of undetectable or 
low detectable-stable PSA indicates the presence of residual prostatic cells in the body, which 
may be benign or malignant and in the surgical bed or disseminated. We do not know whether 
the positive association between chlordecone exposure and biochemical recurrence reflects a 
direct effect on the PSA production of residual cells or the proliferation of these cells, which 
in turn secrete PSA. PSA secretion is generally under androgen regulation, but chlordecone 
shows low affinity binding to the androgen receptor (AR) and acts as an AR antagonist rather 
than agonist.8  Moreover, there is currently no data supporting the involvement of chlordecone 
in AR-dependent or AR-independent mechanisms driving PSA mRNA expression or protein 
secretion.  
We previously reported that chlordecone exposure was associated with an increased 
risk of prostate cancer occurrence and suggested that the estrogenic properties of the molecule 
may explain this association.14  Chlordecone interferes with estradiol signaling through 
binding to the nuclear estrogen receptors α (ERα) and β (ERβ), eliciting agonistic and 
antagonistic effects, respectively. 7,32,33 The ERα mediates the adverse effects of estrogen, 
such as aberrant proliferation, inflammation, and malignancy, whereas the ERβ exerts 
opposite and beneficial effects, such as anti-proliferative, pro-apoptotic, anti-inflammatory, 
and, potentially, anticarcinogenic effects.34 Thus, the combined interaction between the 
agonistic effects of chlordecone on the ERα and the antagonistic effects on the ERβ could 
lead to an imbalance, promoting cell proliferation. It is possible that such interplay could also 
play a role in the proliferation of residual prostatic tumor cells, if present, after radical 
prostatectomy.  
Although biochemical recurrence is never followed by disease progression for some 
patients, it is almost certainly an indicator of persistent disease and an unquestionable risk 
factor for the development of subsequent distant metastases. Indeed, chlordecone has been 
found to promote angiogenesis through ERα activation,35 and both chlordecone and estradiol 
increase expression of the homeostatic chemokine receptor type 4 and enhance vascular cell 
adhesion protein 1 levels.36 Moreover, chlordecone disrupts cell-adherence junctions by 
modulating E-cadherin and β-catenin expression.37 Collectively, these effects participate in 
the tumor cell-microenvironment signaling involved in tumor and metastasis progression for 
several types of cancers, including prostate cancer.38-42 Whether biochemical recurrence 
associated with chlordecone exposure is predictive of an increased risk of metastasis remains 
to explored through the long-term follow up of patients. 
Several epidemiological studies in different locations, including in French West 
Indies, have suggested that exposure to DDE is associated with a higher risk of prostate 
cancer occurrence.12,15,19  However, we did not find a significant association between DDE 
exposure and the risk of biochemical recurrence. DDE is known to inhibit AR-mediated 
effects through direct binding to the AR.8 A recent study has also shown that DDE lowers 
PSA mRNA and protein levels in human prostate cancer cell lines in a dose-dependent 
manner.43 DDE exposure of healthy men is negatively associated with serum concentration of 
5α-dihydrotestosterone,44 the most potent ligand and activator of the AR. Given these 
properties, DDE would have been expected to be associated with a decreased risk of 
biochemical recurrence due to a possible direct effect on PSA production or prostate cell 
growth, itself an AR-mediated effect. DDE may also have an agonistic effect on ERα. 45 It is 
therefore difficult to predict the net effect of DDE on the prostate, given the potential effects 
on both the AR and ERα.46, 47  
The literature concerning PCBs is less clear, as there are contradictory and even 
opposite observations regarding their association with the risk of PCa occurrence.11-13,16-18 
Here, we did not observe a significant association between PCB-153 exposure and the risk of 
biochemical recurrence, in either direction. Unlike dioxin-like PCBs, non-dioxin-like PCBs 
(including PCB-153), which are the most highly prevalent PCBs in the environment,48  do not 
interact substantially with the aryl hydrocarbon receptor and may act through other pathways, 
such as steroid hormone signaling.6 Non-dioxin-like PCBs may interact with genomic and 
non-genomic ER pathways and exhibit both estrogenic and anti-estrogenic properties, 
depending on the in vivo or in vitro experimental models.6,9,10 The multiple potential steroidal 
mechanisms of non-dioxin-like PCBs are yet to be totally deciphered and it is thus difficult to 
have a clear picture of their actions.  
In conclusions, our results shown that exposure to chlordecone, an environmental 
EDCs with estrogenic properties, at the time of prostate cancer diagnosis is significantly 
associated with a risk of biochemical recurrence after prostatectomy. Increasing evidence 
suggests that estrogens are critical players in human prostate cancer.49,50 Our findings add 
support to the hypothesis that human exposure to environmental estrogens may influence 
prostate cancer progression  
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Table 1  
Baseline characteristics of patients and HR (95% CIs) of biochemical recurrence of 
prostate cancer 
Characteristic n (%)  HR (95%CI) 
Age (years), [mean (interquartile range)] 63.7 (58.5-67.9) 1.01 (0.98-1.04) 
Caribbean origin   
     French West Indies  313 (96.0) 1.0 (reference) 
     Haiti or Dominica 13 (4.0) 1.43 (0.58-3.43) 
Education    
     Primary  165 (60.0) 1.0 (reference) 
     Secondary 97 (29.9) 0.64 (0.39-1.04) 
     High school and higher 62 (19.1) 0.98 (0.38-1.20) 
     Missing data 2  
Body mass index (kg/m²)    
     < 25 141 (43.3) 1.0 (reference) 
     25 to 30 154 (47.2) 1.19 (0.76-1.85) 
     > 30 31 (9.5) 2.18 (1.15-4.14) 
Smoking    
   Never 202 (62.5) 1.0 (reference) 
   Former or current 121 (37.5) 0.91 (0.59-1.40) 
   Missing data 3  
Alcohol consumption    
   Never 49 (15.1) 1.0 (reference) 
   Ever 275 (84.9) 1.02 (0.58-1.80) 
   Missing data 2  
Type 2 diabetes    
   No 266 (83.7) 1.0 (reference) 
   Yes 52 (16.3) 1.03 (0.59-1.79) 
   Missing data 8  
Family history of prostate cancer    
   No 180 (55.6) 1.0 (reference) 
   Yes 89 (27.5) 1.60 (1.01-2.54) 
   Do not know 55 (16.9) 1.47 (0.85-2.55) 
   Missing data 2  
Pre-operative PSA (ng/mL) [median (interquartile range)] 7.3 (5.5-10.5) 1.32 (0.90-1.94) 
Total lipids (g/L) [median (interquartile range] 5.2 (4.6-5.6) 0.96 (0.78-1.18) 
Pathological Gleason grade   
   ISUP Gleason grade 2 or lower  280 (85.9) 1.0 (reference) 
   ISUP Gleason grade 3 or higher 46 (14.1) 3.68 (2.36-5.74) 
Pathological stage   
    pT2 and N0 269 (82.5) 1.0 (reference) 
    pT3a or pT3b, or N
+
 57 (17.5) 2.90 (1.88-4.49) 
Surgical margins   
    Negative 233 (71.5) 1.0 (reference) 
    Positive 93 (28.5) 2.72 (1.80-4.10) 
Tumor density (%) [median (interquartile range)] 9.0 (5.0-17.0) 2.62 (1.60-4.29) 
Biochemical recurrence status   
     No  233 (71.5)  
     Yes 93 (28.5)  
Follow-up time (years) [median (interquartile range)] 6.1 (2.8-8.9)  
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Table 2 
Detection and concentrations of persistent organic pollutants in plasma samples from 
the study population (µg/L)  
 
POPs 
a
 
 
Detection frequency (%) Percentile   
10th 25th 50th 75th Maximum 
Chlordecone 80.1 <LOD 0.16 0.38 0.69 19.1 
DDE 94.7 0.38 0.93 2.33 4.68 40.1 
DDD 22.1 <LOD <LOD <LOD <LOD 0.95 
DDT 28.0 <LOD <LOD <LOD 0.06 2.3 
PCB-28 47.7 <LOD <LOD <LOD 0.24 2.94 
PCB-52 50.0 <LD <LD 0.05 0.39 6.72 
PCB-101 45.7 <LOD <LOD <LOD 0.12 0.83 
PCB-118 57.3 <LOD <LOD 0.07 0.16 2.38 
PCB-138 98.3 0.16 0.29 0.53 0.82 3.60 
PCB-153 97.0 0.20 0.38 0.76 1.17 5.96 
PCB-180 96.3 0.23 0.35 0.59 0.86 3.16 
-HCH 28.0 <LOD <LOD <LOD <LOD 1.1 
-HCH 35.3 <LOD <LOD <LOD 0.05 2.2 
-HCH 19.5 <LOD <LOD <LOD <LOD 0.60 
 
a
 Chlordecone was measured in 326 plasma samples, and other POPs in 300 plasma samples. 
PCB congeners 18, 77, 101, 105, 110, 126, 128, 143, 149, 156, 169, 170, 183, 187, 194, 195, 
206, and 209 were below the LOD in all plasma samples.
This article is protected by copyright. All rights reserved
A
cc
ep
te
d 
A
rti
cl
e
Table 3  
HR (95% CIs) of biochemical recurrence of prostate cancer according to quartile of chlordecone, DDE and PCB-153 exposure 
 
Exposure Without 
biochemical 
recurrence  
(n) 
With  
biochemical 
recurrence  
(n) 
Crude HR (95% CI) Adjusted HR (95% CI) 
a
 Adjusted HR (95% CI) 
b
 
Chlordecone (µg/L)      
   < 0.16 62 18 1.0 (reference) 1.0 (reference) 1.0 (reference) 
   0.16 -  0.37 57 27 1.50 (0.83-2.73) 1.63 (0.89-2.98) 1.55 (0.81-2.93) 
   0.38 -  0.68 64 18 0.97 (0.50-1.86) 1.03 (0.53-2.00) 0.94 (0.46-1.90) 
   > 0.69 50 30 1.96 (1.09-3.52) 2.51 (1.39-4.56) 2.62 (1.40-4.90) 
  P trend   0.01 0.002 0.002 
DDE (µg/L)      
   < 0.93 54 21 1.0 (reference) 1.0 (reference) 1.0 (reference) 
   0.93 -  2.31 53 21 0.84 (0.46-1.54) 0.54 (0.29-1.01) 0.54 (0.27-1.04) 
   2.32 -  4.66 48 27 1.18 (0.67-2.09) 0.91 (0,50-1.66) 0.87 (0.45-1.71) 
   > 4.67 59 17 0.71 (0.37-1.35) 0.55 (0.29-1.06) 0.50 (0.24-1.05) 
P trend   0.89 0.51 0.35 
PCB-153 (µg/L)      
   < 0.38 54 20 1.0 (reference) 1.0 (reference) 1.0 (reference) 
   0.38 - <0.74 51 25 1.28 (0.71-2.30) 1.09 (0.59-1.99) 1.19 (0.62-2.28) 
   0.75 -  1.16 55 20 0.94 (0.50-1.74) 0.88 (0.47-1.64) 1.05 (0.53-2.06) 
   > 1.17 60 21 1.04 (0.56-1.92) 0.93 (0.49-1.76) 1.12 (0.55-2.28) 
P trend   0.81 0.41 0.82 
 
 
a
 For chlordecone: adjusted for pathological Gleason grade, pathological  stage, surgical margins, body mass index, and family history of prostate 
cancer; For DDE or PCB-153:  adjusted for pathological Gleason grade, pathological stage, surgical margins, and body mass index. 
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b
 For chlordecone: adjusted for pathological Gleason grade, pathological stage, surgical margins, family history of prostate, body mass index, 
DDE, and PCB-153; For DDE:  adjusted for pathological Gleason grade, pathological stage, surgical margins, body mass index, chlordecone, 
and PCB-153; For PCB-153: adjusted for pathological Gleason grade, pathological stage, surgical margins, body mass index, chlordecone, and 
DDE. 
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Table 4  
Sensitivity analysis among patients with negative surgical margins, low-grade pathological Gleason score, and organ-confined disease.  
HRs (95% CIs) of biochemical recurrence of prostate cancer according to quartile of chlordecone, DDE and PCB-153 exposure 
 
Exposure Without 
biochemical 
recurrence  
(n) 
With  
biochemical 
recurrence  
(n) 
Crude HR (95% CI) Adjusted HR (95% CI) 
a
 
Chlordecone (µg/L)     
   < 0.16 35 6 1.0 (reference) 1.0 (reference) 
   0.16 -  0.37 43 6 0.87 (0.28-2.70) 0.61 (0.18-2.09) 
   0.38 -  0.68 42 3 0.44 (0.11-1.75) 0.42 (0.10-1.79) 
   > 0.69 34 15 2.48 (0.96-6.39) 2.98 (1.06-8.38) 
  P trend   0.008 0.003 
DDE (µg/L)     
   < 0.93 38 6 1.0 (reference) 1.0 (reference) 
   0.93 -  2.31 31 7 1.24 (0.42-3.70) 0.99 (0.30-3.32) 
   2.32 -  4.66 34 8 1.24 (0.43-3.58) 1.32 (0.39-4.48) 
   > 4.67 39 8 1.25 (0.43-3.62) 1.21 (0.36-4.05) 
P trend   0.66 0.96 
PCB-153 (µg/L)     
   < 0.38 42 7 1.0 (reference) 1.0 (reference) 
   0.38 - <0.74 31 8 1.49 (0.54-4.10) 1.36 (0.48-3.85) 
   0.75 -  1.16 30 8 1.33 (0.48-3.68) 0.92 (0.29-2.92) 
   > 1.17 33 6 0.98 (0.33-2.93) 0.82 (0.25-2.72) 
P trend   0.94 0.89 
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a
 For chlordecone: adjusted for family history of prostate cancer, body mass index, DDE and PCB-153; For DDE:  adjusted for body mass index, 
chlordecone, and PCB-153; For PCB-153: adjusted for body mass index, chlordecone, and DDE. 
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Some environmental chemicals can mimic human hormones, and may spur cancer progression. 
Here, the authors studied the effect of three prevalent organic chemicals on prostate cancer 
recurrence: the estrogenic insecticide chlordecone; DDE, a stable metabolite of DDT which has 
anti-androgenic properties; and PCB-153, which has estrogenic and anti-estrogenic properties. 
No effect was associated with DDE or PCB-153. However, those in the highest exposure 
quartile for chlordecone had 2-fold increased risk of biochemical recurrence, defined as two 
consecutive elevated PSA measurements, after prostatectomy. These findings add to the 
evidence that environmental estrogens could promote cancer progression. 
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